Drug resistant HIV: Behaviors and characteristics among Los Angeles men who have sex with men with new HIV diagnosis. by Gorbach, Pamina M et al.
UCLA
UCLA Previously Published Works
Title
Drug resistant HIV: Behaviors and characteristics among Los Angeles men who have sex 
with men with new HIV diagnosis.
Permalink
https://escholarship.org/uc/item/38b04783
Journal
PloS one, 12(3)
ISSN
1932-6203
Authors
Gorbach, Pamina M
Javanbakht, Marjan
Bornfleth, Lorelei
et al.
Publication Date
2017
DOI
10.1371/journal.pone.0173892
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
RESEARCH ARTICLE
Drug resistant HIV: Behaviors and
characteristics among Los Angeles men who
have sex with men with new HIV diagnosis
Pamina M. Gorbach1,2*, Marjan Javanbakht1, Lorelei Bornfleth2, Robert K. Bolan3,
Martha Lewis Blum4
1 Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, CA,
United States of America, 2 Division of Infectious Diseases, Department of Medicine, David Geffen School of
Medicine, University of California, Los Angeles, CA, United States of America, 3 The Los Angeles Gay,
Lesbian and Transgender Health Center, Los Angeles, CA, United States of America, 4 Department of
Medicine, Community Hospital of the Monterey Peninsula, Monterey County, Department of Public Health,
Monterey, CA, United States of America
* pgorbach@ucla.edu
Abstract
Epidemiology of drug resistant HIV has focused on trends and less attention has been given
to identification of factors, especially behaviors including substance use, in acquisition of
drug-resistant HIV. From 2009 to 2012 The Metromates Study enrolled and followed for one
year men who have sex with men (MSM) seeking testing for HIV in a community clinic in Los
Angeles assessing those testing positive for acute and recent HIV infection. Behavioral data
were collected via Computer-Assisted Self-Interview from 125 classified as newly HIV
infected and 91 as chronically infected (newly HIV-diagnosed); specimens were available
and viable for resistance testing for 154 of the 216 HIV positives with new diagnoses. In this
community clinic we found prevalence of resistance among MSM with new HIV-diagnosis
was 19.5% (n = 30/154) with no difference by recency of HIV infection. Sexual partnership
characteristics were associated with resistance; those who reported transgendered sex
partners had a higher prevalence of resistance as compared to those who did not report
transgendered sex partners (40% vs. 17%; p value = 0.04), while those who reported having
a main partner had a lower prevalence of drug resistance (12% vs. 24%; p value = 0.07). In
multivariable analyses adjusting for HIV recency and antiviral use, reporting a main partner
decreased odds [adjusted odds ratio (AOR) 0.34; 95% confidence interval (CI) 0.13–0.87],
reporting a transgendered partnered increased odds (AOR = 3.37; 95% CI 0.95–12.43);
and being African American increased odds of drug resistance (AOR = 5.63, 95%CI 1.41–
22.38). This suggests African American MSM and TG individuals in Los Angeles represent
pockets of exceptional risk that will require special approaches to prevention and care to
enhance their own health and reduce their likelihood to support transmission of drug resis-
tance in the US.
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Introduction
Among those with a new diagnosis of HIV infection, some are infected by a strain of HIV-1
resistant to one or more drugs, known as primary or transmitted drug resistance (TDR) [1].
The efficiency of such transmission between individuals is relatively low[2] but evidence is
growing that such resistance can stem from untreated individuals and strains can persist in
populations for many years[3, 4]. In a meta-analysis the median overall TDR prevalence glob-
ally ranged from 2.8% to 11.5%, and non-nucleoside reverse transcriptase inhibitor (NNRTI)
associated TDR increased in North America[5]. Levels of TDR in the US and Europe among
men who have sex with men (MSM) appear similar although pockets of higher prevalence
ranging from 12–24% have been documented[6, 7] [8]. There have been few studies of behav-
ioral factors associated with resistance [9, 10]. There are conflicting findings about substance
use. Methamphetamine use was associated with acquisition of multi-drug resistant virus in
New York in 2005[11] and we confirmed this in 2008 along with other substance use in South-
ern California[9]. However, other studies have not shown association of substance use and
resistance even among injection drug users[12]. To contribute to understanding the role of
substance use and other risk factors in acquisition of drug-resistant HIV we conducted a study
of MSM with new HIV diagnoses in Los Angeles in a community clinic setting.
Materials and methods
Between 2009–2012 321 MSM enrolled in the NIDA funded Metromates Cohort Study con-
ducted at The Los Angeles LGBT Center, a community-based organization providing sexual
health services, social services and HIV care in Los Angeles. Men at least 18 years of age report-
ing sex with a man in the past 12 months who sought HIV testing at the LGBT Center were
offered an opportunity to undergo a consent process including a written consent with a full
description of the study with choices about if and how to participate in specimen donation,
and then were provided a copy of their written consent form (the original was saved with
study materials). Those who tested HIV-positive provided a specimen for testing of recency of
infection using the Vironostika detuned assay (BioSystems Laboratory in San Francisco) a vali-
dated assay for use of detection of early HIV infection[13, 14]; negative antibody results were
tested for acute infection using RNA nucleic acid amplification testing (NAAT). Those testing
positive (n = 216) were all verified as newly diagnosed, with a subset classified as recently
infected (125) using one of the following four criteria: (1) documentation of a negative HIV
test<12 months prior to enrollment; (2) a NAAT positive test result on a specimen negative
by HIV antibody testing; (3) result indicative of recent infection from a detuned serologic
assay; and (4) documentation of recent infection by a referring physician. The remaining 91
who had a positive rapid HIV test yet showed no evidence of recent infection using the assays
described above were classified as newly HIV-diagnosed (but not newly infected) and 105
were HIV-negative. A subset of the HIV-positive men (173/216) consented to providing
plasma samples for storage for future analysis and 154 of these were viable for resistance test-
ing (n = 17 of the newly diagnosed did not have sufficient viral load for genotyping and two
were missing baseline data). Analysis was restricted to 154 men with resistance testing data.
No differences noted between those excluded and the analyzed sample except for more testing
done in those without a main partner compared to those with (76.2% vs. 64.6; p value = 0.05).
Behavioral data
A Computer-Assisted Self-Interview (CASI) assessed sexual partner type (main partner, casual
partner, female partner, and transgender partner); types of sexual activity (group sex and
transactional sex); substance use (marijuana, cocaine, inhalants, opioids, methamphetamine,
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and injection drug use). Also assessed was use of ARV drugs for treatment, pre-exposure pro-
phylaxis (PrEP) or post-exposure prophylaxis (PEP), substance use, and sexual behavior.
“Treatment status” was determined from reports of date starting ARVs as some men started
ARVs before enrollment due to a lag between communication of an HIV positive test result
and study enrollment. Initiation of care was not an exclusion criteria for this analysis. The
questions and scales used in this study were developed from two previous studies of men with
acute HIV infection or previous diagnosis; with careful attention to included comparable ques-
tions/measures to the previous cohort that identified behavioral factors associated with resis-
tant HIV [15–17]. The Partnership Assessment Scale and definitions of partnership types were
developed using sociometric analyses in previous studies and research on partnerships in gen-
eral as well as qualitative research [18].
Resistance testing
HIV genotyping was performed using stored plasma samples collected at study enrollment.
The testing of those assessed as acutely infected (n = 104) was conducted at the HIV Genotyp-
ing Laboratory at Johns Hopkins University (JHU) and the other new diagnoses at University
of California Los Angeles (UCLA) School of Medicine (n = 69). Testing at JHU was conducted
using the ViroSeq HIV Genotyping System v2.8 (Celera Diagnostics, Alameda, CA). This sys-
tem provides HIV sequences for the region encoding HIV protease (amino acids 1–99) and
HIV reverse transcriptase (amino acids 1–335). Testing at UCLA was done using the UltraSens
Viral Isolation kit (Qiagen) according to the manufacturer’s protocol. The Reverse Transcrip-
tase (RT) and Protease (PRO) genes were amplified and sequenced according to the previously
published protocol of Snoeck et al. using SuperScript III RT (Invitrogen) for RT and KOD
high fidelity polymerase (Novagen) for PCR. PCR products were directly sequenced using the
BigDye v3.1 Kit (Applied Biosystems) according to the manufacturer’s protocol using the
primers described in Snoeck et al[19]. Sequences were edited and assembled using BioEdit
(Ibis Biosciences, Carlsbad, CA). ARV drug resistance was determined by consulting the Stan-
ford University HIV Drug Resistance Database (http://hivdb.stanford.edu/). Samples were
classified as “resistant” if results indicated reduced sensitivity to at least one class of ARVs.
Statistical methods
Differences in ARV drug resistance to at least one class of HIV drugs by demographics and
behaviors were evaluated using t-tests, Wilcoxon rank sum, chi-square methods, Fisher’s exact
tests and multivariable logistic regression analysis. Behaviors included in the analyses were
selected based on findings from the research team’s previous work with this population
and this topic[9, 17] as well as the existing literature. All analyses were conducted using SAS
software, version 9.2 (SAS Institute Inc., Cary, NC). Study procedures were reviewed and
approved by the UCLA IRB and the LGBT Center’s Research Committee.
Results
Among the 154 recently HIV-diagnosed MSM with testable plasma the mean age was 30 years,
nearly half identified as Hispanic (48%), followed by white (29%) and African American
(17%); 58% were identified as having an acute/recent HIV-infection. The median number of
sexual partners in the past 12-months was eight [interquartile range (IQR) 4–20], with a
median of two anonymous partners and one one-time partner. More than half the participants
(n = 79; 52%) reported substance use in the past 3 months, including marijuana (41%), meth-
amphetamine (20%), cocaine (15%), and opioids (3%). Eleven (7%) reported sex with both
men and women; and 30 (19.5%) reported a transgender partner in the last 12 months; 30
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(19.5%) reported transactional sex in the past 3 months. Between screening and enrollment 30
men (19%) had initiated ARV therapy. Among these HIV positive men more methamphet-
amine use was reported among newly infected than chronically infected (33% vs. 20%; p
value = 0.07).
Drug resistance to at least one class of ARVs was identified in 30 (19.5%) of the 154 partici-
pants. Most of the resistance was to NNRTIs: 25/30 cases of resistance. The prevalence of ARV
resistance did not vary significantly by HIV diagnosis group (Table 1) although the higher
prevalence among those newly diagnosed versus newly infected (24.6% versus 16.1%) may
have been significant in a larger sample size. There was no significant difference in prevalence
of resistance between between those reporting ARV use and reporting no ARV use (22.2% ver-
sus 19.4%, respectively; p value = 0.76). Futhermore, when we excluded the 20 reporting ARV
use resistance prevalence did not change, remaining 19.4%. Sexual partnership characteristics
were associated with resistance; those who reported transgendered sex partners had a higher
prevalence of resistance as compared to those who did not report transgendered sex partners
40% vs. 17%; p value = 0.04), while those who reported having a main partner had a lower
prevalence of drug resistance (12% vs. 24%; p value = 0.07). No other behavioral factors were
associated with resistance including number of sexual encounters, unprotected anal inter-
course (UAI), and having a known HIV-positive partner. There were more methamphetamine
users with resistance but the difference was not statistically significant (25.8% vs. 18.2%; p
value = 0.34). In multivariable analyses adjusting for HIV group (recent or chronic infection)
were conducted with and without those reporting ARV use; and the ARV use was adjusted for
in the models in which those individuals were included (Table 1).
Reporting a main partner decreased odds of drug resistance [adjusted odds ratio (AOR)
0.34; 95% confidence interval (CI) 0.13–0.87 with ARV users and marginally without the ARV
users AOR 0.39, 95% CI 0.14–1.10], reporting a transgendered partnered increased odds
(AOR = 3.37; 95% CI 0.95–12.43 with ARV users and AOR 5.15, 95% CI 1.14, 23.21 without
ARV users); and being African American increased odds of drug resistance (AOR = 5.63, 95%
CI 1.41–22.38 with ARV users and AOR 4.40, 95% CI 1.05, 18.40 without ARV users).
Discussion
The prevalence of drug resistance of 19.5% among MSM in Los Angeles with new HIV diagno-
sis is relatively high compared to other reports [20] even when the analysis is restricted to those
with acute/recent HIV infection (16.1%). This sample included those with new HIV diagnosis
but no evidence of recent infection, therefore, some of this resistance may be acquired although
there is evidence that transmitted resistance can persist for months or years in the absence of
drug exposure[21, 22]. Concerns that this high level of resistance may be due to underreporting
previous use of ARVs are lessened because of our study design: our subjects were recruited after
seeking HIV testing on their own at a community clinic. This differentiates them from partici-
pants in other studies who were recruited from general community, not from among those who
had sought testing on their own. General community samples captured individuals with HIV
with a range of experience (for example in care, out of care but known positive, unknown posi-
tive)[23]. Because all participants in our study were obtaining HIV testing on their own initia-
tive these individuals were subject to fewer motivations to underreport ARV use at the time of
testing to affect their eligibility for a study enrollment (that included a financial incentive to par-
ticipate). Moreover, all our participants completed their study questionnaires after they had
been enrolled in the study, insuring their responses about ARV use did not affect their eligibility
for the study. Reports of ARVs detected at relatively high levels in specimens of those reporting
no ARV use and no knowledge of a previous diagnosis[8],[10] have come from intervention
Behaviors and drug resistant HIV in Los Angeles MSM
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Table 1. Prevalence and factors associated with antiretroviral drug resistance among men newly infected and/or newly diagnosed with HIV, Los
Angeles, 2009–2012 (n = 154).
n / N % P value OR (95% CI) AOR (95% CI) AOR (excluding those on ARVs
n = 22)
(95% CI)
Age, years^ 0.78 1.01 (0.96–1.06)
Resistance 30.8
(8.8)
— — — —
No resistance 30.4
(7.5)
— — — —
Race/ethnicity 0.09
African American 9 / 23 39.1 4.07 (1.22–
13.53)
5.63 (1.41–
22.38)
4.40 (1.05–
18.40)
Hispanic 14 / 73 19.2 1.50 (0.53–4.25) 2.30 (0.74–7.11) 1.83 (0.55–6.06)
Other 1 / 10 10.0 0.70 (0.08–6.60) 0.88 (0.09–8.83) 0.84 (0.08–8.65)
White 6 / 44 13.6 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
HIV group 0.20
Newly infected 15 / 93 16.1 1.30 (0.87–1.95) 1.23 (0.78–1.94) 1.30 (0.79–2.13)
Newly diagnosed 15 / 61 24.6 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
Antiretroviral therapy 0.76
Yes 4 / 18 22.2 1.19 (0.36–3.90) 1.02 (0.27–3.89) — —
No 26 / 134 19.4 1.00 (Reference) 1.00 (Reference) — —
Gender of sex partners, past 12 months 0.45
Men only 27 / 142 19.0 1.00 (Reference) — — — —
Men and Women 3 / 11 27.3 1.60 (0.40–6.42) — — — —
Transgendered sex partner, past 12
months
0.04
Yes 6 / 15 40.0 3.17 (1.03–9.73) 3.37 (0.95–
12.43)
5.15 (1.14–
23.21)
No 24 / 138 17.4 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
Group sex 0.32
Yes 13 / 54 24.1 1.51 (0.67–3.41) — — — —
No 17 / 98 17.4 1.00 (Reference) — — — —
Transactional sex, past 3
months
0.52
Yes 4 / 16 25.0 1.41 (0.42–4.73) — — — —
No 26 / 136 19.1 1.00 (Reference) — — — —
Main partner, past 12 months 0.07
Yes 8 / 64 12.5 0.44 (0.18–1.07) 0.34 (0.13–0.87) 0.39 (0.14–1.10)
No 22 / 90 24.4 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
Casual partner, past 12
months
0.02
Yes 24 / 95 25.3 2.99 (1.14–7.82) — — — —
No 6 / 59 10.2 1.00 (Reference) — — — —
Anonymous partner, past 12 months 0.85
Yes 7 / 38 18.4 0.91 (0.36–2.33) — — — —
No 23 / 116 19.8 1.00 (Reference) — — — —
Substance use, past 3 months
Marijuana 0.36
Yes 10 / 62 16.1 0.67 (0.29–1.16) — — — —
No 20 / 90 22.2 1.00 (Reference) — — — —
Cocaine 0.76
(Continued )
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trials that incentivized HIV testing and determined study eligibility with further incentives
based on a report of no ARV use and HIV results–a different source population and enrollment
context from our study. Intervention trials that base receipt of monetary incentives on eligibility
criteria are particularly vulnerable to inaccurate self-reports; the design of our study removed
this potential reporting bias.
The increased risk of resistance among men who have sex with transgendered (TG) partners is
a new finding. TGs represent a marginalized group of individuals among whom adherence to
HIV treatment is particularly poor[24] and who may consequently be more likely to develop resis-
tance. Because there was no difference by race/ethnicity for men reporting sex with TGs there
does not appear to be an overlap in sexual networks of specific race/ethnicity groupings with
those networks in which there are many TGs. There is also evidence HIV positive TG sex workers
tend to use condoms less than MSM[25], suggesting another pathway that men who have sex with
TGs may be more likely to acquire HIV. Our finding of this association of drug resistance with
sexual exposure to TGs was strong; and remained the only factor associated with resistance except
for race after we excluded those reporting use of ARVs from our analysis. TG represent a group
who struggle with accessing and maintaining HIV care and services and this suggests their chal-
lenges may be contributing to specific transmission dynamics of resistant HIV.
Our findings point to the role of the main partner in providing protection against acquiring
resistant virus and the increased risk with having casual partners. Clearly the more exposures,
the more likely one of these is to someone with a resistant virus. Yet this also suggests that sex-
ual networks are playing an increasingly important role in the transmission of resistance. It
points to the need to counsel men without main partners that when they have unprotected sex
with casual partners whose HIV status or use of therapy is unknown they may be at higher risk
of acquiring resistant virus and that this has the potential to affect their therapeutic options.
Table 1. (Continued)
n / N % P value OR (95% CI) AOR (95% CI) AOR (excluding those on ARVs
n = 22)
(95% CI)
Yes 4 / 23 17.4 0.83 (0.26–2.66) — — — —
No 26 / 129 20.2 1.00 (Reference) — — — —
Methamphetamine 0.34
Yes 8 / 31 25.8 1.57 (0.62–3.96) — — — —
No 22 / 121 18.2 1.00 (Reference) — — — —
Inhalants 0.98
Yes 1 / 5 20.0 1.02 (0.11–9.45) — — — —
No 29 / 147 19.7 1.00 (Reference) — — — —
Opiods 0.26
Yes 2 / 5 40.0 2.83 (0.45–
17.77)
— — — —
No 28 / 147 19.1 1.00 (Reference) — — — —
Any drugs (excluding marijuana) 0.32
Yes 13 / 54 24.1 1.51 (0.67–3.41) 2.25 (0.89–5.67) 2.44 (0.90–6.65)
No 17 / 98 17.4 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
Injection Drug Use, past 12 months 0.78
Yes 2 / 12 16.7 1.25 (0.26–6.03) — — — —
No 28 / 140 20.0 1.00 (Reference) — — — —
Abbreviations. OR = Odds Ratio; CI = Confidence Interval; AOR = Adjusted Odds Ratio.
^Data represent mean and standard deviation.
https://doi.org/10.1371/journal.pone.0173892.t001
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Our finding that African American MSM were more likely than other MSM in Los Angeles
to acquire resistance raises continuing concerns about the epidemic among African American
MSM. These men are most likely to acquire HIV in general in the US–with African Americans
representing half of all new infections in 2009[26] and African American MSM accounting for
twice as many new infections as either white or Hispanic/Latino gay and bisexual men in 2010
[27]. This suggests African American MSM may be having sexual encounters in very dense
networks with high concordance of virus and also be in sexual networks of men with lower
ARV adherence than other MSM, enhancing their likelihood of exposure to a resistant virus. A
review of the literature of HIV among Black MSM in the US noted they were less likely to be
adherent to HIV therapy than other MSM[28]. Finally, it should be noted that more of the
African American MSM with drug resistance were in the newly diagnosed, not newly infected
group, however, our analyses showed no significant difference by diagnosis timing.
Given the challenges of enrolling individuals into studies at the time of their HIV diagnosis
and identifying those with acute or recent infection in any community, the sample size for this
study was relatively small. This limited the power to more sensitively detect factors associated
with resistance that were low prevalence. Although the study used computer-assisted inter-
viewing and emphasized the conduct of the study in the most sensitive way for individuals
with new HIV diagnosis, behavioral reports are always prone to mis-reporting and that could
result in misclassification of participants in the analysis. Finally, the study and was initiated
and tools developed in 2008 and earlier, when awareness of and well-developed tools for study-
ing transgender individuals were not yet evolved fully limiting our ability to better study how
them.
Our findings support the rationale for examining behavioral characteristics of resistance
because we could not confirm findings from earlier studies that identified strong use, notably
methamphetamine use, as a driver of multi-resistant HIV[29] suggesting a potential biological
factor in drug use if it could be isolated from other behavioral factors. The role of substances
on development of resistance requires further research but our findings suggest may not be a
current priority. Phylogenetic studies have shown that certain strains of the virus can circulate
in sexual networks identifiable by specific characteristics such as geography, age, substance use
patterns, or other social characteristics. Resistant strains of the virus are likely doing the same;
therefore understanding partner characteristics may point to networks with higher prevalence
of such viruses and suggest prioritizing regular resistance testing on men from such networks.
Finally, as individual characteristics may be of minimal use in identifying those more likely to
have resistant virus, the characteristics of their partners may be a better marker of elevated risk
and help focus counseling on the source of the resistance. Partner characteristics have been
shown to be predictors of other risks such as acquisition of HIV and other STIs; our findings
provide more evidence of the importance of studying such factors in the epidemiology of HIV
and other STIs.
These findings indicate trends in HIV transmission patterns among MSM in Los Angeles.
As a case of multi-drug resistant HIV has been documented among an individual on pre-expo-
sure prophylaxis with emtricitabine (FTC)–tenofovir disoproxil fumarate (TDF) that was iden-
tified as transmitted and not acquired[30] there clearly remains a need to continue to monitor
HIV resistance and factors associated with its transmission. A strength of our study is the abil-
ity to identify local factors associated with HIV acquisition and transmission of drug resistance
in a community setting. Our sample was diverse by race/ethnicity and socio-economic status,
and while all were MSM many reported female or transgender partners. Our findings indicate
different transmission dynamics are emerging and the role of race/ethnicity and partnering
patterns in the epidemic is becoming more apparent. African American MSM and TG individ-
uals may have lower access to care and poorer adherence to therapy than other men, creating
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pockets of exceptional risk that will require special approaches to prevention and care to
enhance their own health and reduce their likelihood to support transmission of drug resis-
tance in the US.
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